Clinical Trial Update: Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019)

View source ↗

Summary

Expanded access to Everolimus for an individual patient with Gastrointestinal Stromal Tumor has ended and is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Afinitor (everolimus)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Gastrointestinal Stromal Tumor | Status: NO_LONGER_AVAILABLE